Cointime

Biolex Therapeutics

company

About

Biolex Therapeutics developed therapeutic proteins and monoclonal antibodies that had been optimized to enhance their efficacy and potency.

  • 1 - 10

Highlights

Total Funding Amount
$24.40M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$24.40M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 1997
Number Of Employee
1 - 10
Operating Status
Close

Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$24.40M
Biolex Therapeutics has raised a total of $24.40M in funding over 2 rounds. Their latest funding was raised on Aug 21, 2003 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 21, 2003 Series Unknown $24.40M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Biolex Therapeutics is funded by 2 investors. Academy Centennial Fund and The Trelys Funds are the most recent investors.
Investor Name Lead Investor Funding Round
Academy Centennial Fund — Series Unknown
The Trelys Funds — Series Unknown
Cointime
Content
Company